DRONABINOL TREATMENT OF DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

• US 20070072938A1
• Filed: 05/15/2006
• Published: 03/29/2007
• Est. Priority Date: 05/13/2005
• Status: Abandoned Application

• Current Assignee: Unimed Pharmaceuticals LLC (Abbott Laboratories Incorporated)
• Original Assignee: Unimed Pharmaceuticals LLC (Abbott Laboratories Incorporated)
• Inventors: Rose, Kevin
• Application Number:
  US11/383,387
• Publication Number:
  US 20070072938A1
• Time in Patent Office: Days
• US Class Current: 514/454
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics

Abstract

In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-tetrahydrocannabinol and methods of administering such compositions prior to the administration of chemotherapy to prevent or reduce the development of delayed chemotherapy-induced nausea and vomiting.

Claims

1. A method of treating delayed chemotherapy induced nausea and vomiting comprising administering to a patient in need thereof a pharmaceutically effective amount of dronabinol prior to the patient receiving a dose of chemotherapy.

2. The method of claim 1, wherein the dronabinol is administered between about 24 hours to about 48 hours prior to a dose of chemotherapy.

3. The method of claim 1, wherein the pharmaceutically effective amount of dronabinol is about 2.5 mg/day to about 40 mg/day.

4. The method of claim 1, wherein the dronabinol is also administered to the patient after a dose of chemotherapy.

5. The method of claim 4, wherein the dronabinol is administered to the patient at least once a day for up to about five days after a dose of chemotherapy.

6. The method of claim 5, wherein the pharmaceutically effective amount of dronabinol is varied between the third day and the fifth day after a dose of chemotherapy.

7. The method of claim 6, wherein the pharmaceutically effective amount of dronabinol is increased.

8. The method of claim 1, wherein the dronabinol is administered to the patient in a dosage form selected from the group consisting of a metered dose inhaler, a capsule, a tablet, or a nasal spray.

9. The method of claim 1, wherein the dronabinol is administered to the patient through a transdermal delivery system.

10. The method of claim 9, wherein the transdermal delivery system is a patch.

11. A method of treating delayed chemotherapy induced nausea and vomiting comprising administering to a patient in need thereof a pharmaceutically effective amount of dronabinol prior to and following the patient receiving a dose of chemotherapy.

12. The method of claim 11, wherein the dronabinol is administered between about 24 hours to about 48 hours prior to a dose of chemotherapy.

13. The method of claim 11, wherein the pharmaceutically effective amount of dronabinol is about 2.5 mg/day to about 40 mg/day.

14. The method of claim 11, wherein the dronabinol is administered to the patient at least once a day for up to about five days after a dose of chemotherapy.

15. The method of claim 14, wherein the pharmaceutically effective amount of dronabinol is varied between the third day and the fifth day after a dose of chemotherapy.

16. The method of claim 15, wherein the pharmaceutically effective amount of dronabinol is increased.

17. The method of claim 11, wherein the dronabinol is administered to the patient in a dosage form selected from the group consisting of a metered dose inhaler, a capsule, a tablet, or a nasal spray.

18. The method of claim 11, wherein the dronabinol is administered to the patient through a transdermal delivery system.

19. The method of claim 18, wherein the transdermal delivery system is a patch.

20. A method of treating delayed chemotherapy induced nausea and vomiting comprising administering to a patient in need thereof a pharmaceutically effective amount of dronabinol and ondansetron prior to and following the patient receiving a dose of chemotherapy.